Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 34Neoplasm Metastasis 7Neoplasms 4Urinary Bladder Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Breast Neoplasms, Male 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Metastatic Breast Cancer With Intracranial Metastases 1Melanoma 1Inflammatory Breast Neoplasms 1Her2 Positive Metastatic Breast Cancer 1Head and Neck Neoplasms 1HER2 Positive Esophagogastric Cancer 1GastroEsophageal Cancer 1Esophageal Squamous Cell Carcinoma 1Diarrhea 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Carcinoma 1Breast Diseases 1Brain Neoplasms 1

Interventions

Carboplatin 7Pemetrexed 5pembrolizumab 4Gemcitabine 4osimertinib 3Sorafenib 3Paclitaxel 3Interleukin-2 3Cyclophosphamide 3Cisplatin 3seocalcitol 2selinexor 2patritumab 2liposomal doxorubicin 2interferon gamma-1b 2fludarabine 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Irinotecan 2Erlotinib Hydrochloride 2DNA 2Celecoxib 2Capecitabine 2Bleomycin 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2volociximab 1thioredoxin reductase inhibitor AM12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma × Lapatinib × Clear all
NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Novartis

Phase 3 Terminated
37 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡